NetworkNewsBreaks – Predictive Oncology Inc. (NA
Post# of 281
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced its entry into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of approximately 4,222,288 shares of its common stock. The company expects gross proceeds of approximately $7.4 million, with each of the shares sold a purchase price of $1.75, in the registered direct offering priced at-the-market under Nasdaq rules. Predictive Oncology has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of approximately 2,111,114 shares of common stock. The closing of the offering is expected to occur on or about Feb. 16, 2021, subject to the satisfaction of customary conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer